NO951633L - 5-arylindol-derivater og deres anvendelse som serotonin (5-HT1) agonister - Google Patents

5-arylindol-derivater og deres anvendelse som serotonin (5-HT1) agonister

Info

Publication number
NO951633L
NO951633L NO951633A NO951633A NO951633L NO 951633 L NO951633 L NO 951633L NO 951633 A NO951633 A NO 951633A NO 951633 A NO951633 A NO 951633A NO 951633 L NO951633 L NO 951633L
Authority
NO
Norway
Prior art keywords
alkyl
aryl
hydrogen
ring
membered
Prior art date
Application number
NO951633A
Other languages
English (en)
Other versions
NO309652B1 (no
NO951633D0 (no
Inventor
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO951633D0 publication Critical patent/NO951633D0/no
Publication of NO951633L publication Critical patent/NO951633L/no
Publication of NO309652B1 publication Critical patent/NO309652B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NO951633A 1992-11-02 1995-04-28 5-arylindol-derivater og deres anvendelse, samt farmasöytisk blanding NO309652B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
PCT/US1993/009790 WO1994010171A1 (en) 1992-11-02 1993-10-19 5-arylindole derivatives and their use as serotonin (5-ht1) agonists

Publications (3)

Publication Number Publication Date
NO951633D0 NO951633D0 (no) 1995-04-28
NO951633L true NO951633L (no) 1995-04-28
NO309652B1 NO309652B1 (no) 2001-03-05

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951633A NO309652B1 (no) 1992-11-02 1995-04-28 5-arylindol-derivater og deres anvendelse, samt farmasöytisk blanding

Country Status (27)

Country Link
US (1) US5886008A (no)
EP (2) EP0666858B1 (no)
JP (1) JP2788551B2 (no)
KR (1) KR0163371B1 (no)
CN (1) CN1051313C (no)
AT (1) ATE202102T1 (no)
AU (1) AU685066B2 (no)
BR (1) BR9307348A (no)
CA (2) CA2148380C (no)
CZ (1) CZ283001B6 (no)
DE (1) DE69330351T2 (no)
DK (1) DK0666858T3 (no)
EG (1) EG20396A (no)
ES (1) ES2157224T3 (no)
FI (2) FI111257B (no)
GR (1) GR3036579T3 (no)
HU (1) HU222235B1 (no)
IL (1) IL107386A (no)
MY (1) MY109696A (no)
NO (1) NO309652B1 (no)
NZ (1) NZ257059A (no)
PL (1) PL176091B1 (no)
PT (1) PT666858E (no)
RU (1) RU2134266C1 (no)
TW (1) TW251284B (no)
WO (1) WO1994010171A1 (no)
ZA (1) ZA938137B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
CA2169179C (en) * 1993-08-31 2000-02-29 John E. Macor 5-arylindole derivatives
KR970701182A (ko) * 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
AU702322B2 (en) * 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
KR20060119871A (ko) * 2003-08-21 2006-11-24 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ３―치환된 이미다조피리딘 ｃ―ｋｉｔ 억제제
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
ES2346157T3 (es) * 2006-03-22 2010-10-11 Janssen Pharmaceutica N.V. Derivados de alquilaminas ciclicas como inhibidores de la interaccion entre mdm2 y p53.
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2016255431B2 (en) 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
WO2016176449A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
ES2767707T3 (es) 2015-04-29 2020-06-18 Janssen Pharmaceutica Nv Compuestos de indolona y su uso como moduladores de receptor AMPA
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
RU2727179C2 (ru) 2015-11-06 2020-07-21 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
CA2091562C (en) * 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
CA2340999C (en) 2005-01-04
RU2134266C1 (ru) 1999-08-10
EP0666858B1 (en) 2001-06-13
CN1094727A (zh) 1994-11-09
FI111257B (fi) 2003-06-30
PL308669A1 (en) 1995-08-21
FI934825L (fi) 1994-05-03
PL176091B1 (pl) 1999-04-30
ES2157224T3 (es) 2001-08-16
JPH07508759A (ja) 1995-09-28
CZ110895A3 (en) 1995-11-15
FI20002505A7 (fi) 2000-11-15
FI20002505L (fi) 2000-11-15
CN1051313C (zh) 2000-04-12
NO309652B1 (no) 2001-03-05
KR950704313A (ko) 1995-11-17
RU95109927A (ru) 1997-01-10
DK0666858T3 (da) 2001-08-27
AU5329494A (en) 1994-05-24
NO951633D0 (no) 1995-04-28
CA2340999A1 (en) 1994-05-11
NZ257059A (en) 1997-07-27
US5886008A (en) 1999-03-23
HU222235B1 (hu) 2003-05-28
JP2788551B2 (ja) 1998-08-20
CA2148380A1 (en) 1994-05-11
ZA938137B (en) 1995-05-02
AU685066B2 (en) 1998-01-15
CZ283001B6 (cs) 1997-12-17
BR9307348A (pt) 1999-05-11
DE69330351T2 (de) 2001-09-20
EP1094064A1 (en) 2001-04-25
PT666858E (pt) 2001-09-28
FI934825A0 (fi) 1993-11-01
MY109696A (en) 1997-04-30
TW251284B (no) 1995-07-11
EP0666858A1 (en) 1995-08-16
GR3036579T3 (en) 2001-12-31
WO1994010171A1 (en) 1994-05-11
CA2148380C (en) 2001-08-14
EG20396A (en) 1999-02-28
KR0163371B1 (ko) 1998-12-01
DE69330351D1 (de) 2001-07-19
ATE202102T1 (de) 2001-06-15
HUT66011A (en) 1994-08-29
IL107386A (en) 1999-03-12
IL107386A0 (en) 1994-01-25

Similar Documents

Publication Publication Date Title
DK0666858T3 (da) 5-arylindolderivater og deres anvendelse som serotonin(5-HT1)-agonister
DK0716649T3 (da) 5-Arylindolderivater
CA2124206A1 (en) Indole derivatives
NO983970L (no) Tricykliske forbindelser, deres fremstilling og anvendelse
DE3781716D1 (de) Mittel zur ortsspezifischen alkylierung.
DE69827785D1 (de) 1,4-substituierte cyclische aminderivate
CA2117643A1 (en) Indole Derivatives
FI953710A0 (fi) Uusia pyrrolokarbatsoleja
ATE71619T1 (de) Pyridazinon-derivate.
ATE231487T1 (de) 2-phenoxyanilin-derivate
KR930703309A (ko) 치환된 벤조푸란 유도체의 제조방법
ATE230391T1 (de) Pyrrolidin derivate, anti-ulcus und antibakterielle arzneimittel
DE69005318D1 (de) 1,8-Benzonaphthyridinderivate, ihre Herstellung und diese enthaltende Zusammensetzungen.
ATE134607T1 (de) Tetrahydronaphtalenderivate, ihre herstellung und ihre therapeutische verwendung
NO981689L (no) Naftylpiperasinderivater
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees